Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Methoxymethane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methoxymethane SCHEMBL11145545 | 1.00 | GAA (0.54) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL29991938 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| P-Xylene SCHEMBL8660591 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL1705904 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL31313 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL11432043 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL34 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL5068661 | 0.93 | GAA (0.62) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| SCHEMBL6621981 | 0.91 | ALDH1A1 (0.54) | GAAALDH1A1SMN1; SMN2LMNATDP1 | |
| Water SCHEMBL214962 | 0.90 | GAA (0.59) | GAAALDH1A1SMN1; SMN2LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674224-A | MPEG4-abacavir and preparation method and application thereof | 天津迈德新医药科技有限公司 | 2017-05-17 | — | — | CN | claimed |
| US-12625134-B2 | Complex liquid crystal droplets | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2025261923-A1 | POLYURETHANE-BASED ADHESIVE WITH SWITCHABLE DEBONDING | HENKEL AG & CO. KGAA (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-9745273-B2 | Phenazine derivatives as anti-neoplastic agents and anti-infective agents | UNIVERSITETET I OSLO (NO) | 2017-08-29 | — | — | US | disclosed |
| CN-106674224-A | MPEG4-abacavir and preparation method and application thereof | 天津迈德新医药科技有限公司 | 2017-05-17 | — | — | CN | disclosed |
| EP-3063136-A2 | PHENAZINE DERIVATIVES AS ANTI-CANCER AND ANTI-INFECTIVE AGENTS | Universitetet I Oslo (NO) | 2016-09-07 | — | — | EP | disclosed |
| US-20160251320-A1 | Compounds | UNIVERSITÉ CLAUDE BERNARD LYON 1 (FR) | 2016-09-01 | — | — | US | disclosed |
| WO-2015063516-A2 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2015-05-07 | — | — | WO | disclosed |
| EP-2250212-A1 | SEMICONDUCTOR NANOPARTICLE CAPPING AGENTS | Nanoco Technologies Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106810-A1 | SEMICONDUCTOR NANOPARTICLE CAPPING AGENTS | NANOCO TECHNOLOGIES LIMITED (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12625134-B2 | Complex liquid crystal droplets | MAFG, SFN, FLNB | GAA 4883/4885ALDH1A1 4423/4885SMN1; SMN2 806/4885 |
| US-20160251320-A1 | Compounds | NISCH, MDN1, PIR | GAA 3194/4885ALDH1A1 4618/4885SMN1; SMN2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.